Armata Pharmaceuticals Inc (ARMP)
AMEXHealth CareBiotechnologySnapshot 2026-11-04
$3.00-4.46%
Close 2026-11-05 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ARMP
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Expenses & Income | |||||||||||||
| R&D Expenses | — | — | — | — | — | — | — | 9.8 | 8.4 | 2.9 | 5.7 | 4.0 | 5.8 |
| Operating Income | (40.7) | (36.6) | (42.4) | (40.9) | (36.9) | (23.8) | (21.6) | (19.8) | (17.7) | (16.2) | (23.4) | (10.2) | (14.1) |
| Earnings from Continuing Operations | |||||||||||||
| Interest Expense | — | — | — | — | 0.0 | 0.1 | 0.6 | 0.9 | — | — | 0.0 | — | 0.0 |
| Interest & Investment Income | — | — | — | 0.2 | 0.0 | 0.0 | 0.0 | 0.1 | — | — | — | — | — |
| Net Interest Expenses | — | — | — | — | (0.0) | 0.1 | 0.6 | 0.8 | — | — | — | — | — |
| Asset Writedown | — | — | — | — | — | — | — | — | 1.9 | 5.8 | 9.5 | — | — |
| EBT, Incl. Unusual Items | — | (173.8) | (18.9) | (69.0) | (0.0) | (23.2) | (22.2) | (19.5) | (16.7) | (14.1) | (19.4) | (0.6) | — |
| Income Tax Expense | — | — | — | — | — | — | — | — | (0.3) | (1.3) | (0.6) | (0.1) | — |
| Net Income | |||||||||||||
| Net Income | (192.2) | (173.8) | (18.9) | (69.0) | (36.9) | (23.2) | (22.2) | (19.5) | (16.7) | (12.8) | (18.8) | (0.5) | 23.1 |
| Per Share | |||||||||||||
| Basic EPS | (5.23) | (4.80) | (0.52) | (1.91) | (1.08) | (0.96) | (1.35) | (2.49) | (3.59) | (2.01) | — | (1.99) | 4.21 |
| Diluted EPS | (3.10) | (4.80) | (0.89) | (1.91) | (1.08) | (0.96) | (1.35) | (2.55) | (3.59) | (2.18) | — | (1.99) | (2.33) |
| Basic Weighted Avg Shares | 36.7 | 36.2 | 36.2 | 36.1 | 34.3 | 24.1 | 16.4 | 7.8 | 4.7 | 6.4 | — | 5.4 | 3.7 |
| Diluted Weighted Avg Shares | 62.0 | 36.2 | 59.1 | 36.1 | 34.3 | 24.1 | 16.4 | 8.0 | 4.7 | 6.6 | — | 5.4 | 5.9 |
| Supplemental | |||||||||||||
| EBITDA | — | — | (41.1) | (39.9) | (36.1) | — | — | — | — | — | — | — | — |
| EBIT | (40.7) | (36.6) | (42.4) | (40.9) | (36.9) | (23.8) | (21.6) | (19.8) | (17.7) | (16.2) | (23.4) | (10.2) | (14.1) |
| Effective Tax Rate | — | — | — | — | — | — | — | — | 2.0% | 9.2% | 2.9% | 12.4% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.